Mouse models for gastric cancer: Matching models to biological questions

AR Poh; RJJ O'Donoghue; M Ernst; TL Putoczki

Journal article

Mouse models for gastric cancer: Matching models to biological questions

AR Poh, RJJ O'Donoghue, M Ernst, TL Putoczki

Journal of Gastroenterology and Hepatology Australia | Published : 2016

DOI: 10.1111/jgh.13297

Download PDF

Abstract

Gastric cancer is the third leading cause of cancer-related mortality worldwide. This is in part due to the asymptomatic nature of the disease, which often results in late-stage diagnosis, at which point there are limited treatment options. Even when treated successfully, gastric cancer patients have a high risk of tumor recurrence and acquired drug resistance. It is vital to gain a better understanding of the molecular mechanisms underlying gastric cancer pathogenesis to facilitate the design of new-targeted therapies that may improve patient survival. A number of chemically and genetically engineered mouse models of gastric cancer have provided significant insight into the contribution of ..

View full abstract

University of Melbourne Researchers

Tracy Putoczki Author

Related Projects (3)

ESTABLISHING AND VALIDATING A NEW THERPAUETIC TARGET FOR COLON AND STOMACH CANCER

Cancers of the stomach and the colon are a major health burden. One of the central signaling molecules that drives these cancers is called S..

MOLECULAR DISSECTION OF ABERRANT IL6/GP130 AND TGFB SIGNALING IN THE PATHOGENESIS OF INTERSTITIAL PNEUMONITIS

Interstitial pneumonia (IP) is frequently observed in the group of lung diseases which affect the transfer of oxygen from inhaled air into t..

IMPROVING TARGETED THERAPY FOR COLORECTAL CANCER

Colorectal cancer (CRC) is one of the most common causes of cancer-associated death in the world. We aim to understand why some CRC patients..

Grants

Awarded by Cancer Therapeutics Cooperative Research Centre

Funding Acknowledgements

The work in the laboratory of T.L.P. is supported by the Victorian State Government Operational Infrastructure Support and the National Health and Medical Research Council Australia (NHMRC) project grants nos. 1008614, and 1080498, Cancer Australia project grant no. 1407672, and Worldwide Cancer Research project grant no. 14-1197. The work in the laboratory of M. E. is supported by Ludwig Cancer Research, the Victorian State Government Operational Infrastructure Support, the IRIISS scheme of the NHMRC, and NHMRC project grants nos. 1069024, 1067244, and 1092788. A. R. P. is supported by an Australian Post Graduate Award (APA) and a Cancer Therapeutics CRC (Ctx) PhD Top-Up Scholarship. R. O'D received project grant support from NHMRC no. 1025239 and the Victorian Cancer Agency no. ECSG13014.